Pasithea Therapeutics Corp. — Investor Relations & Filings
Filings indexed
301
across all filing types
Latest filing
2026-05-15
Interim / Quarterly Rep…
Country
US
United States of America
Listing
US
KTTA
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. The company develops new therapeutics for neurological and psychiatric conditions, with a primary focus on Neurofibromatosis type 1 (NF1), a disorder causing tumor growth along nerves, and Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease. Its research also targets Multiple Sclerosis (MS), a chronic autoimmune disease of the CNS, and schizophrenia, a disabling psychiatric illness. The company's pipeline additionally includes treatments for solid tumors.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| QUARTERLY REPORT | 2026-05-15 | English | |
| 8-K - PASITHEA THERAPEUTICS CORP. (0001841330) (Filer) | 2026-02-20 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G Filing | 2026-02-12 | English |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 46363349 | QUARTERLY REPORT | 2026-05-15 | English | ||
| 32899636 | 8-K - PASITHEA THERAPEUTICS CORP. (0001841330) (Filer) | 2026-02-20 | English | ||
| 32021647 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32021493 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 32021479 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 32021505 | SCHEDULE 13G Filing | 2026-02-12 | English | ||
| 32021490 | S-8 Filing | 2026-01-30 | English | ||
| 32021563 | 8-K Filing | 2026-01-28 | English | ||
| 13367478 | POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 | 2026-01-26 | English | ||
|
2025
6 filings
| |||||
| 13367481 | DEFINITIVE PROXY STATEMENT | 2025-12-29 | English | ||
| 13367482 | PRELIMINARY PROXY STATEMENT | 2025-12-19 | English | ||
| 13367480 | CURRENT REPORT | 2025-12-15 | English | ||
| 13367483 | Major Shareholding Notification 2025 | 2025-12-05 | English | ||
| 13367484 | Major Shareholding Notification 2025 | 2025-12-05 | English | ||
| 13367489 | CURRENT REPORT | 2025-12-02 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Asarina Pharma AB
A biotechnology company in liquidation, formerly focused on…
|
ASAP | SE | Professional, scientific and te… |
|
Atara Biotherapeutics, Inc.
Develops off-the-shelf allogeneic T-cell immunotherapies fo…
|
ATRA | US | Professional, scientific and te… |
|
ATUM CO., LTD.
An integrated biologics development partner offering servic…
|
355690 | KR | Professional, scientific and te… |
|
AUREKA LIMITED
Accelerates drug discovery and development using AI and com…
|
AKA | AU | Professional, scientific and te… |
|
Avalo Therapeutics, Inc.
Clinical-stage biotech developing treatments for immune-med…
|
AVTX | US | Professional, scientific and te… |
|
Avalyn Pharma Inc.
Developing innovative inhaled therapies for rare respirator…
|
AVLN | US | Professional, scientific and te… |
|
Azenta, Inc.
Offers sample management, storage, and multiomics solutions…
|
AZTA | US | Professional, scientific and te… |
|
Baijin Life Science Holdings Limited
An investment holding company operating in biopharmaceutica…
|
1466 | HK | Professional, scientific and te… |
|
BCAL DIAGNOSTICS LIMITED
Developing a non-invasive blood test for early breast cance…
|
BDX | AU | Professional, scientific and te… |
|
BEBETTER MED INC.
Develops small molecule therapeutics for oncology, metaboli…
|
688759 | CN | Professional, scientific and te… |
Pasithea Therapeutics Corp. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35389/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35389 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35389 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35389 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35389}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Pasithea Therapeutics Corp. (id: 35389)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.